必应词典为您提供The-Netherlands-Cancer-Institute的释义,网络释义: 荷兰癌症研究院;荷兰癌症研究所;
Cephalosporinsthird-generationsantibacterialMinimum inhibitory concentrations (MIC) were determined against 662 recent clinical isolates for eight cephalosporins representing first, second and third generation compounds. All four third-generation cephalosporins tested (cefoperaxone, cefotaxime, ceftazidime and moxa...
A risk management plan should be tailored to each woman, particularly taking into account the level of her short-term (rather than life-time) risk, her lifestyle plans (such as child-bearing), competing risks (particularly in women with a prior cancer) and her personal preferences. The risk...
Objective To evaluate penile squamous cell carcinoma (PSCC) incidence and centralisation trends in the Netherlands over the past three decades, as well as the effect of centralisation of PSCC care o...
Division of Molecular Pathology, The Netherlands Cancer Institute, Oncode Institute, Amsterdam, CX, The Netherlands Annegien Broeks & Jos Jonkers Department of Biomolecular Engineering, University of California Santa Cruz, Santa Cruz, CA, USA Angela N. Brooks, David Haan, Maximillian G. Marin, Thom...
Cancer Molecular Diagnostics Laboratory, Department of Oncology, University of Cambridge, Cambridge, UK Shubha Anand & Jose-Ezequiel Martin Department of Scientific Administration, The Netherlands Cancer Institute, Amsterdam, The Netherlands Danny Baars & Ruud van der Noll ...
Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands René Bernards Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA Elizabeth Jaffee Ludwig Institute for Cancer Research and University of Lausanne, Lausanne, Switze...
Jan Paul Medema, PhD, Amsterdam University Medical Centers and Oncode Institute, The Netherlands Jan Paul Medema studied Chemistry in Leiden, the Netherlands, graduating in 1991 with a specialisation in biochemistry and medical biochemistry. He continued his training under the guidance of Professor Hans...
469. Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands. 470. Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo O310, Norway. 471. Department of Oncology, University of Cambridge, Cambridge CB2 1TN, UK. ...
Assignee: The Netherlands Cancer Institute (Amsterdam, NL) Merck Sharp & Dohme Corp. (Rahway, NJ, US) Primary Class: 435/6.14 Other Classes: 536/23.1, 702/19 International Classes: C07H21/00; C12Q1/68; C12M1/00; G01N33/53; C12N15/09; C12Q1/02; G01N33/48; G01N33/566; G01N...